Enterococcus Faecium Infections-Pipeline Review, H1 2015

Enterococcus Faecium Infections-Pipeline Review, H1 2015

  • Products Id :- GMDHC6528IDB
  • |
  • Pages: 131
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Enterococcus Faecium Infections-Pipeline Review, H1 2015


Global Markets Direct's, 'Enterococcus Faecium Infections-Pipeline Review, H1 2015', provides an overview of the Enterococcus Faecium Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Enterococcus Faecium Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Enterococcus Faecium Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Enterococcus Faecium Infections Overview 10

Therapeutics Development 11

Pipeline Products for Enterococcus Faecium Infections-Overview 11

Pipeline Products for Enterococcus Faecium Infections-Comparative Analysis 12

Enterococcus Faecium Infections-Therapeutics under Development by Companies 13

Enterococcus Faecium Infections-Therapeutics under Investigation by Universities/Institutes 15

Enterococcus Faecium Infections-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Enterococcus Faecium Infections-Products under Development by Companies 18

Enterococcus Faecium Infections-Products under Investigation by Universities/Institutes 21

Enterococcus Faecium Infections-Companies Involved in Therapeutics Development 22

Alchemia Limited 22

Alvogen, Inc. 23

Aphios Corporation 24

Cellceutix Corporation 25

ConjuGon, Inc. 26

ContraFect Corporation 27

Enanta Pharmaceuticals, Inc. 28

Helix BioMedix, Inc. 29

LegoChem Biosciences, Inc 30

Lytix Biopharma AS 31

Melinta Therapeutics, Inc 32

MGB Biopharma Limited 33

Microbiotix, Inc. 34

MicuRx Pharmaceuticals, Inc. 35

Nabriva Therapeutics AG 36

NovaBay Pharmaceuticals, Inc. 37

Novan, Inc. 38

NovoBiotic Pharmaceuticals, LLC 39

Omnia Molecular Ltd. 40

Oragenics, Inc. 41

Sealife PHARMA GMBH 42

Sentinella Pharmaceuticals, Inc. 43

Sumitomo Dainippon Pharma Co., Ltd. 44

TAXIS Pharmaceuticals, Inc. 45

Wockhardt Limited 46

Enterococcus Faecium Infections-Therapeutics Assessment 47

Assessment by Monotherapy Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

auriclosene-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

brilacidin tetrahydrochloride-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

CF-304-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

chrysophaentin-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

closthioamide-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

EDP-788-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Epimerox-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

GP-505-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

HB-1345-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

HT-01-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

HT-02-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

IBN-1-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

LCB-010371-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

LCB-010699-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

lefamulin-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

LTX-109-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Marinus-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

MBX-1162-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

MGBBP-3-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

MRX-I-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

MU-1140-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

NAI-107-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

NAI-603-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

NVN-1000-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

NVN-4428-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

RX-05-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

RXP-873-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

SLP-0904-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

SLP-0905-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

SM-295291-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

SM-369926-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Small Molecule for Bacterial Infections-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

SP-2078-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Teixobactin-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

TXA-709-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

WCK-4086-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

Enterococcus Faecium Infections-Recent Pipeline Updates 106

Enterococcus Faecium Infections-Dormant Projects 124

Enterococcus Faecium Infections-Discontinued Products 126

Enterococcus Faecium Infections-Product Development Milestones 127

Featured News & Press Releases 127

Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 127

Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 127

Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 128

Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 128

May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 129

Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 129

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Tables

Number of Products under Development for Enterococcus Faecium Infections, H1 2015 11

Number of Products under Development for Enterococcus Faecium Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Development by Companies, H1 2015 (Contd..2) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Enterococcus Faecium Infections-Pipeline by Alchemia Limited, H1 2015 22

Enterococcus Faecium Infections-Pipeline by Alvogen, Inc., H1 2015 23

Enterococcus Faecium Infections-Pipeline by Aphios Corporation, H1 2015 24

Enterococcus Faecium Infections-Pipeline by Cellceutix Corporation, H1 2015 25

Enterococcus Faecium Infections-Pipeline by ConjuGon, Inc., H1 2015 26

Enterococcus Faecium Infections-Pipeline by ContraFect Corporation, H1 2015 27

Enterococcus Faecium Infections-Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 28

Enterococcus Faecium Infections-Pipeline by Helix BioMedix, Inc., H1 2015 29

Enterococcus Faecium Infections-Pipeline by LegoChem Biosciences, Inc, H1 2015 30

Enterococcus Faecium Infections-Pipeline by Lytix Biopharma AS, H1 2015 31

Enterococcus Faecium Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 32

Enterococcus Faecium Infections-Pipeline by MGB Biopharma Limited, H1 2015 33

Enterococcus Faecium Infections-Pipeline by Microbiotix, Inc., H1 2015 34

Enterococcus Faecium Infections-Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 35

Enterococcus Faecium Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 36

Enterococcus Faecium Infections-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 37

Enterococcus Faecium Infections-Pipeline by Novan, Inc., H1 2015 38

Enterococcus Faecium Infections-Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015 39

Enterococcus Faecium Infections-Pipeline by Omnia Molecular Ltd., H1 2015 40

Enterococcus Faecium Infections-Pipeline by Oragenics, Inc., H1 2015 41

Enterococcus Faecium Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 42

Enterococcus Faecium Infections-Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015 43

Enterococcus Faecium Infections-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 44

Enterococcus Faecium Infections-Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015 45

Enterococcus Faecium Infections-Pipeline by Wockhardt Limited, H1 2015 46

Assessment by Monotherapy Products, H1 2015 47

Number of Products by Stage and Target, H1 2015 49

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Enterococcus Faecium Infections Therapeutics-Recent Pipeline Updates, H1 2015 106

Enterococcus Faecium Infections-Dormant Projects, H1 2015 124

Enterococcus Faecium Infections-Dormant Projects (Contd..1), H1 2015 125

Enterococcus Faecium Infections-Discontinued Products, H1 2015 126

List of Figures

Number of Products under Development for Enterococcus Faecium Infections, H1 2015 11

Number of Products under Development for Enterococcus Faecium Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 47

Number of Products by Top 10 Targets, H1 2015 48

Number of Products by Stage and Top 10 Targets, H1 2015 49

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 51

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Alchemia Limited

Alvogen, Inc.

Aphios Corporation

Cellceutix Corporation

ConjuGon, Inc.

ContraFect Corporation

Enanta Pharmaceuticals, Inc.

Helix BioMedix, Inc.

LegoChem Biosciences, Inc

Lytix Biopharma AS

Melinta Therapeutics, Inc

MGB Biopharma Limited

Microbiotix, Inc.

MicuRx Pharmaceuticals, Inc.

Nabriva Therapeutics AG

NovaBay Pharmaceuticals, Inc.

Novan, Inc.

NovoBiotic Pharmaceuticals, LLC

Omnia Molecular Ltd.

Oragenics, Inc.


Sentinella Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

TAXIS Pharmaceuticals, Inc.

Wockhardt Limited

Enterococcus Faecium Infections Therapeutic Products under Development, Key Players in Enterococcus Faecium Infections Therapeutics, Enterococcus Faecium Infections Pipeline Overview, Enterococcus Faecium Infections Pipeline, Enterococcus Faecium Infections Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com